NCT04411212

G-CSF and PRP in Patients With Recurrent Implantation Failure

Granulocyte Colony-stimulating Factor and Platelet-rich Plasma Group in Patients With Recurrent Implantation Failure

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 112 (estimated)
• Sponsor: Riyadh Fertility and Reproductive Health center · Academic / Other
• Sex: Female
• Age: 1 Year – 35 Years
• Healthy volunteers: Not accepted

Summary

The aim of this randomized controlled trial is to determine whether granulocyte colony-stimulating factor and platelet-rich plasma can be used to enhance the IVF-ET outcomes in patients with recurrent implantation failure

Conditions

• Infertility,Female

Interventions

Type	Name	Description
DRUG	Granulocyte colony-stimulating factor and platelet-rich plasma group	Antagonist protocol is used . Oocyte retrieval under transvaginal ultrasound guidance is performed 34 to 36 hours after HCG administration. Autologous platelet-rich plasma is prepared from the blood using the two step centrifuge process. Under ultrasound guidance and complete aseptic procedures, 1 ml of the PRP is infused inside the uterus while performing the mock embryo transfer. Moreover, G-CSF (Filgrastim®, 300μg/0.5ml) is injected subcutaneously. G-CSF is injected weekly until the 12th gestation week or negative pregnancy test.
OTHER	Control group	Antagonist protocol is used . Oocyte retrieval under transvaginal ultrasound guidance is performed 34 to 36 hours after HCG administration. Mock embryo transfer is performed without injecting anything inside the uterus.

Timeline

• Start date: 2020-05-28
• Primary completion: 2020-12-31
• Completion: 2021-03-31
• First posted: 2020-06-02
• Last updated: 2020-06-02

Locations

1 site across 1 country: Egypt